Back To Schedule
#338: Evolving Methods in Pain Trials: Evaluating Abuse Deterrence, Drug Interactions, and Appropriate Patient Selection
Chair
Vice President, Clinical Pharmacology, Early Phase, INC Research
Dr. Setnik has been working in the area of CNS research and clinical drug development for over 16 years and is an expert in the area of abuse and dependence potential evaluation of drugs. Dr. Setnik is currently the Vice President of Clinical Pharmacology at INC Early Phase and oversees...
Read More →
Speakers
Director of Pharmacometrics, Early Phase, INC Research
Dr Galina Bernstein received PhD in Biochemistry from Moscow State University, postdoctoral training from College of Pharmacy, U of Michigan, and pharmacokinetics training at Pfizer GRD PDM department. She has 15+ years’ experience in analytics, PK and PK/PD modeling for IVD, small...
Read More →AW
Director, Regulatory Affairs, Pfizer Ltd
Andrew Whiles has 29 years’ regulatory experience in researching , registering and maintaining pharmaceuticals and devices on the market. Over the last four years he has focused on early development regulatory strategies from Phase 1 through to Proof of concept studies within the...
Read More →
Wednesday June 29, 2016 2:00pm - 3:15pm EDT
201A
Pennsylvania Convention Center 1101 Arch Street, Philadelphia, PA 19107 USA
Trk 04: Preclin Transl-Early Clin Dev,
Symposium
- Credit Type ACPE, CME, IACET, RN
- Audience Intermediate
- Featured Topics Precision-Personalized Medicine-Targeted Therapy, Risk Evaluation and Mitigation Strategies (REMS)
- Interest Area Clinical Safety & Pharmacovigilance, Pharmaceutics, Statistics, R&D - Strategic Issues, Clinical Research
- format json
- Interest Area Clinical Safety & Pharmacovigilance,Pharmaceutics,Statistics,R&D / Strategic Issues,Clinical Research
- Featured Topics Precision/Personalized Medicine/Targeted Therapy,Risk Evaluation and Mitigation Strategies (REMS)
- Credit Type ACPE, CME, IACET, RN
- Tags Symposium